Modality
siRNA
MOA
CDK4/6i
Target
SGLT2
Pathway
Sphingolipid
Fabry
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
Jan 2020
→ Oct 2029
Phase 1Current
NCT06788478
1,849 pts·Fabry
2020-01→2029-10·Recruiting
1,849 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-043.5y awayInterim· Fabry
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2029-10-04 · 3.5y away
Fabry
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06788478 | Phase 1 | Fabry | Recruiting | 1849 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 |